Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases by Sperber, Kirk et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
Pediatric Rheumatology
Open Access Review
Systematic review of hydroxychloroquine use in pregnant patients 
with autoimmune diseases
Kirk Sperber*1, Christine Hom2, Chun Peng Chao2, Deborah Shapiro1 and 
Julia Ash1
Address: 1Division of Allergy, Immunology, and Rheumatology, Department of Medicine, New York Medical College, Munger Pavilion, Valhalla, 
NY 10595, USA and 2Division of Rheumatology, Department of Pediatrics, New York Medical College, Munger Pavilion, Valhalla, NY 10595, USA
Email: Kirk Sperber* - kirk_sperber@NYMC.edu; Christine Hom - Christine_hom@NYMC.edu; 
Chun Peng Chao - Chun_PengChao@NYMC.edu; Deborah Shapiro - Deborah_Shapiro@NYMC.edu; Julia Ash - Julia_Ash@NYMC.edu
* Corresponding author    
Abstract
Objective:  The purpose of this study is to compare the incidence of congenital defects,
spontaneous abortions, number of live births, fetal death and pre-maturity in women with
autoimmune diseases taking HCQ during pregnancy.
Methods: The authors searched MEDLINE, Cochrane data base, Ovid-Currents Clinical Medicine,
Ovid-Embase:Drugs and Pharmacology, EBSCO, Web of Science, and SCOPUS using the search
terms HCQ and/or pregnancy. We attempted to identify all clinical trials from 1980 to 2007
regardless of language or publication status. We also searched Cochrane Central Library and http:/
/www.Clinical trials.gov for clinical trials of HCQ and pregnancy. Data were extracted onto
standardized forms and were confirmed.
Results: The odds ratio (OR) of congenital defects in live births of women taking HCQ during
pregnancy was 0.66, 95% confidence intervals (CI) 0.25, 1.75. The OR of a live birth for women
taking HCQ during pregnancy was 1.05 (95% CI 0.58, 1.93). The OR of spontaneous abortion in
women taking HCQ during pregnancy was 0.92 (95% CI 0.49, 1.72). The OR of fetal deaths in
women taking HCQ during pregnancy was 0.97 (95% CI 0.14, 6.54). The OR of pre-mature birth
defined as birth before 37 weeks in women taking HCQ during pregnancy was 1.10 (95% CI 0.75,
1.61).
Conclusion: HCQ is not associated with any increased risk of congenital defects, spontaneous
abortions, fetal death, pre-maturity and decreased numbers of live births in patients with auto-
immune diseases.
Background
The anti-malarial drugs Hydroxychloroquine (HCQ) is
widely used to treat various rheumatic diseases [1]. The
mechanism of action of this drug is to increase the pH in
acidic vesicles, inhibiting receptor mediated endocytosis
that affects many cellular functions including antigen
presentation, toll receptor signaling and post-transcrip-
tional modification of proteins [2-4]. Convincing evi-
dence has accumulated over the past years demonstrating
the efficacy of HCQ in the treatment of auto-immune dis-
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eases including systemic lupus erythematosus (SLE), dis-
coid lupus erythematosus (DLE) and rheumatoid arthritis
(RA) [5,6]. Since many rheumatic diseases affect women
of child bearing age, there have been concerns regarding
potential teratogenic and toxic effects of the drug on the
developing fetus [7,8].
Malformations and other abnormalities after treatment
with higher than the recommended dose of (Chloro-
quine) CQ through pregnancy were reported after intrau-
terine exposure to 500 mg daily of CQ in 3 siblings [9]. In
animal model systems the drug accumulates in the pig-
mented cells in the eye [10,11]. Dose-dependent retinal
toxicity has long been recognized as the major side effect
of HCQ [10,11]. CQ crosses the placenta during preg-
nancy [12]. In an evidence-based guideline evaluating the
risks and benefits of drug therapies during pregnancy, it
was recommended to continue HCQ during pregnancy
and lactation [13]. Although there have been a number of
reviews regarding the use of HCQ during pregnancy [14-
16], to date there has been no meta-analysis analyzing the
effect of HCQ on fetal outcomes in women with various
auto-immune diseases. This systematic review contains a
meta-analysis of the available clinical studies investigating
the use of HCQ during pregnancy and will focus on the
risk of congenital defects, number of live births, spontane-
ous abortions, fetal deaths and pre-maturity in fetuses
born to women taking HCQ.
Materials and methods
Study Selection
We searched the Cochrane data base, Ovid-Current Con-
tents-Clinical Medicine, Ovid-Embase-Drugs and Phar-
macology, EBSCO, Medline, Web of Science, and
SCOPUS using the search terms HCQ and/or pregnancy.
We attempted to identify all clinical trials from 1980 to
2007 regardless of language or publication status. We also
searched Cochrane Library and http://www.Clinical tri
als.gov for clinical trials of HCQ and pregnancy. We also
checked the citations of literature reviews and of all trials
identified in our search. Potentially relevant studies
describing HCQ during pregnancy were retrieved and
examined. Figure 1 is a diagram of the process that was
used to select the studies included in the meta-analysis.
Comparative studies of any design were considered but
those studies without a non-HCQ group were excluded.
Studies were eligible for inclusion if the investigators had
pregnant patients in a non-HCQ treatment group and
reported clinical outcomes in the fetus.
Data Extraction and Quality Assessment
We used previously published methods to determine the
quality of the observational studies used in systematic
reviews [17,18]. The control groups in the included stud-
ies were similar to the HCQ groups for sex, age, criteria for
SLE, DLE, RA or other autoimmune diseases as estab-
lished by American College of Rheumatology (ACR). Two
of the authors extracted all of the data onto a standardized
form that was confirmed by the corresponding author.
The primary outcomes considered in this review were con-
genital defects, spontaneous abortions, fetal deaths, pre-
maturity (birth before 37 weeks of gestation) and live
births. Two raters reviewed and scored the articles inde-
pendently by using a checklist designed by Downs and
Black [19]. In cases of divergence of the results between
the two raters, a third rater reviewed the articles and rated
the quality scores again to choose the most plausible
results. The checklist designed by Downs and Black was
developed for the purpose of quality assessment of both
randomized and nonrandomized studies with health
interventions and consists of five subscales: reporting,
internal validity bias, internal validity confounding, exter-
nal validity, and power [19]. Because six items in the orig-
inal list were related to randomization, and power
calculation, their scores were counted as zero. The maxi-
mum score on the quality scales is 31 points; these were
summed and a higher score is considered to be an indica-
tor of a better quality study. For observational studies, a
quality score of 12 or greater is considered excellent
[19,20].
Identification of relevant articles Figure 1
Identification of relevant articles. We searched the 
Cochrane data base, Ovid-Current Contents-Clinical Medi-
cine, Ovid-Embase-Drugs and Pharmacology, EBSCO, 
Medline, Web of Science, and SCOPUS using the search 
terms HCQ and/or pregnancy for clinical trials from 1980 to 
2007. Potentially relevant studies describing HCQ during 
pregnancy were retrieved and examined.  Pediatric Rheumatology 2009, 7:9 http://www.ped-rheum.com/content/7/1/9
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Data Synthesis and Analysis
Data for congenital defects, spontaneous abortions, fetal
deaths, pre-maturity (Birth before 37 weeks of gestation)
and live births were pooled and analyzed by using the
Cochrane Collaboration Review Manager software (Nor-
dic Cochrane Centre, Copenhagen, Denmark) [20]. We
used Review Manager 4.2 for the analysis. A fixed effect
model of the inverse variance method was used when the
effects were assumed to be homogenous. The random
effect model of the DerSimonian and Laird approach was
used when they were assumed to be heterogeneous [21].
To test the publication bias, funnel plots were drawn with
the treatment effect measure on the horizontal axis and
the study size on the vertical axis, and Harbord test was
performed [22,23]. We used odds ratios (OR) for dichot-
omous variables in this study. Heterogeneity between
studies was assessed by using chi-square and I2 tests, a p
value of less than 0.1 and an I2 value of 50% were consid-
ered high [24].
We calculated the number of subjects that would have to
be included in the meta-analysis for each of the variables,
congenital defects, spontaneous abortions, fetal deaths,
pre-maturity and live births, to have a power of 0.80 and
a one sided p value of 0.05 in pregnant patients taking
HCQ [25]. The likelihood that we would be able to detect
an association between HCQ and congenital defects, live
births, spontaneous abortions, fetal deaths, and pre-matu-
rity is dependent on the magnitude of that association. We
can determine an effect size of 0.20 for congenital defects,
live births, spontaneous abortions, fetal deaths, and pre-
maturity given the number of pregnancies that are
included in this analysis (290 pregnancies on HCQ, 341
pregnancy controls) [26].
Data from randomized placebo-controlled trials (RCTs)
should not be combined with observational studies in a
meta-analysis [17,18]. Since one of the observational
studies was a case controlled study, we used odds ratios
(OR) for the study variables [24].
Role of Funding Source
This study was not funded by any outside agency or phar-
maceutical company.
Results
The literature search for HCQ and/or pregnancy identified
82 abstracts. After review of the abstracts and exclusion of
non-trials and trials that did not compare pregnant
women with auto-immune diseases taking HCQ with a
control group, we identified 5 studies of interest [27-31]
(Figure 1). The studies were published within the past 15
years. Searches of the Cochrane Library and of the http://
www.Clinical Trials.gov website did not return any entries
of HCQ and pregnancy. This was a safety study which
presents considerable difficulties in obtaining sufficient
numbers of patients to include in the meta-analysis. Since
there are more observational studies than experimental
studies in determining the safety of HCQ in pregnancy we
included studies of any design for the meta-analysis. [32].
Seventy-seven articles were excluded including 68 with no
non-HCQ control group and 3 with no outcomes of inter-
est (Figure 1).
Quality assessment of the articles
Four of the 5 studies were observational [27-30] and one
was a randomized placebo controlled double-blinded
trial [31]. Three of the 4 observational studies were pub-
lished as full manuscripts [27-30] and one was presented
as an abstract [30]. One of the observational studies was a
case controlled study [30] while the other 3 were cohort
studies [27-29]. The first observational study had 69
Lupus patients, 13 unclassified connective tissue disease
and 8 patients with primary Sjogren's syndrome [28], the
second observational study included 197 women all diag-
nosed with Lupus [27], the third observational study also
followed 86 Lupus patients [29], as well as the fourth
observational study 142 women with connective tissue
diseases [30] (Additional file 1, Table S1). Only one study
was conducted in the United States [27].
The quality of the studies we identified based on the
Downs and Black checklist ranged from 20 to 25.
Although the double-blinded placebo controlled trail was
of the highest quality we did not include it in our analysis
[31] for statistical reasons as noted previously [17,18]. We
used the Harbord test to investigate funnel plot asymme-
try in the analysis because we measured dichotomous var-
iables [23]. This test avoids the mathematical association
between log odds ratio and its standard error proposed by
Egger et al [18] when there is a substantial intervention
effect, while retaining power compared with alternative
tests. However, false-positives may occur in the presence
of substantial between-study heterogeneity. We did not
observe any substantial heterogeneity in the studies in the
meta-analysis and no publication bias.
OR of congenital defects and live births
Other studies have reported that HCQ is safe to use during
pregnancy but had no control group [35-40]. All 4 of the
studies [27-30] assessed the presence of congenital defects
in babies born to women with autoimmune diseases
(Additional file 1, Table S2 and Figure 2a). The OR for
congenital defects for the pooled data for patients taking
HCQ during pregnancy compared to no drug was 0.66
(95% CI, 0.25, 1.75) which favored HCQ (Additional file
1, Table S2 and Figure 2a).
Consonant with the results obtained for the OR of con-
genital defects, all 4 of the included studies did not reportPediatric Rheumatology 2009, 7:9 http://www.ped-rheum.com/content/7/1/9
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OR of congenital defects and live births Figure 2
OR of congenital defects and live births. The OR for congenital defects (2A)and live births (2B) from the pooled data in 
the HCQ group compared to the control group was determined.Pediatric Rheumatology 2009, 7:9 http://www.ped-rheum.com/content/7/1/9
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any differences in the OR of live births comparing women
who took HCQ compared to the control group (Addi-
tional file 1, Table S2 and Figure 2b.) The OR for live
births of the pooled data in the HCQ group compared to
the control group was 1.10 (95% CI, 0.61, 1.99) (Figure
2b).
OR of spontaneous abortion and fetal death
Women with SLE have a higher incidence of spontaneous
abortions and fetal loss [41,42]. Some investigations have
shown a correlation between disease activity, spontane-
ous abortion, and fetal loss in pregnant SLE patients. Dif-
ferent authors have reported a variety of frequencies of
spontaneous abortions and fetal loss with rates varying
between 11% and 24% [43-47]. Data were available from
the 4 studies [27-30] that defined spontaneous abortion
and fetal death defined as death occurring after 20 weeks
of gestation. The pooled estimate of the OR of spontane-
ous abortion for the patients taking HCQ compared to
placebo was 0.92 (95% CI, 0.49, 1.72) which favored the
HCQ group (Additional file 1, Table S2 and Figure 3a).
In line with the results for spontaneous abortions, all 4
studies reported the OR of fetal death [25-28] (Additional
file 1, Table S2 and Figure 3b). The pooled OR for fetal
death was 0.94 (95% CI 0.14, 6.54) which again favored
the patients taking HCQ. There is variability in the fetal
death rate probably due to the small sample size.
OR of prematurity
Higher incidences of premature births have been
described in SLE patients especially in patients who have
active disease [44,45]. Consistent with the results for con-
genital defects, live births, spontaneous abortions, and
fetal deaths, there was no increased risk of pre-maturity
associated with HCQ treatment. Data are available from
the 4 studies regarding pre-mature death (Additional file
1, Table S2 and Figure 4). The pooled OR was 1.08, (95%
CI, 0.74, 1.57).
Discussion
Our systematic review provides evidence for the use of
HCQ during pregnancy for women with auto-immune
diseases. We identified 3 cohort studies [27-29] and 1
case-controlled study [30] comparing HCQ treatment
with no HCQ treatment in pregnant women with auto-
immune diseases (Figure 1 and Additional file 1, Tables
S1 and S2). We attempted to identify all relevant studies
regarding HCQ and pregnancy by not restricting our liter-
ature search to the English language. It is still possible that
we may have inadvertently omitted other studies that
were not identified in the literature searches of the differ-
ent databases.
Although the Harbord test for dichotomous variables did
not indicate publication bias, citation bias, and database
bias, the number of studies included in our meta-analysis
was only 4 so that it is possible that it may not be able to
distinguish chance from real asymmetry in the funnel
plot. The quality of the studies that were included in this
meta-analysis as determined by the Downs and Black
checklist was excellent despite the fact that they were no
randomized placebo-controlled clinical trials [19,20]. The
scores are listed in Additional file 1, Table S1.
We did not observe any heterogeneity in the results of the
different studies (Figures 2a, b, 3a, and 4) that could have
arisen because of differences in doses of HCQ (200 mg
compared to 400 mg), length of follow up after birth, and
between auto-immune diseases (SLE, DLE, RA, Sjogren's
syndrome), allowing the use of a fixed effect model for.
The only significant heterogeneous result between the
studies was the increased risk of fetal deaths (Figure 3b)
noted where the results were analyzed by using a random-
effects model.
Our study was limited by the lack placebo controlled dou-
ble-blinded studies that compared HCQ therapy with a
control group. The patient populations included in the
studies were fairly homogenous. All of the studies
included pregnant females of child bearing age with
autoimmune disease predominantly Lupus who met the
ACR criteria for diagnosis, all of the patients and the
fetuses were exposed to HCQ at the time of conception
and throughout the pregnancy, all of the studies had a
control group who were not exposed to the drug, and all
reported similar outcomes.
We did not include the 1 RCT [31] because of the difficul-
ties of combining different study designs in meta-analysis
as noted above [17,18]. This study also found no differ-
ences in congenital defects, number of live births, fetal
death, and pre-maturity in patients who were treated with
HCQ compared to those who were not treated with HCQ.
Despite the fact that we performed a meta-analysis, our
studies were underpowered to detect an association
between congenital defects congenital defects, spontane-
ous abortions, fetal deaths, pre-maturity and live births, if
the effect of HCQ is less than 0.2 [48]. We did consider
adding isolated case reports in our analysis given the rarity
of the occurrence of congenital malformations and other
obstetrical complication of this drug [35-40]. However,
we did not include these patients in the statistical analysis
because there were no control groups.
There have been numerous studies using CQ prophylaxis
for malaria during pregnancy. CQ, a pharmacologic ana-
logue of HCQ has been used in Europe to treat auto-
immune diseases and its mechanism of action is identicalPediatric Rheumatology 2009, 7:9 http://www.ped-rheum.com/content/7/1/9
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OR of spontaneous abortion and fetal death Figure 3
OR of spontaneous abortion and fetal death. The pooled estimate of the OR of spontaneous abortion (3A) and fetal 
death (3B) for the patients taking HCQ compared to placebo was determined.Pediatric Rheumatology 2009, 7:9 http://www.ped-rheum.com/content/7/1/9
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to HCQ. In general the doses used for malarial prophy-
laxis are less than those used to treat auto-immune dis-
eases. There is a large meta-analysis published by the
Cochrane database that included 12,638 patients focused
on malaria prevention [32]. No increase in congenital
malformations, live births, spontaneous abortions, fetal
deaths or pre-maturity was noted in patients who used CQ
compared to controls. Although these studies do not
directly prove that CQ is safe for pregnant women with
auto-immune diseases, it is further evidence of the safety
of anti-malaria drugs during pregnancy.
Two of the included studies by Clowse et. al. [27] and Fra-
ssi et al [30] had an increase in fetal death (OR 4.79 95%
CI 0.78, 29.57 and OR 5.40 95% CI 0.26,114.28) in the
placebo while another study by Costedoat-Chalumeau et
al [28] had an OR of 0.08 (95% CI 0.01, 0.60) that
favored HCQ. One possible explanation for this discrep-
ancy is the increased number of patients with anti-cardiol-
ipin antibodies in the HCQ group of Clowse et al [27] and
Frassi et al [30] that may have contributed to the high inci-
dence of fetal deaths seen in both studies.
Since anti-malarials cross the placenta, they have the
potential to cause congenital defects [12]. The first reports
documenting congenital abnormalities and accumulation
of the drug in the eye were described in infants whose
mothers received chloroquine (CQ) [9,33]. However,
recent reports including a Cochrane meta-analysis have
demonstrated that CQ in low doses is safe as malaria
prophylaxis during pregnancy [34]. In addition to the 4
studies that we included in this report, there have been
several uncontrolled studies that have examined the effect
of HCQ therapy on ocular toxicity in babies born to
OR of prematurity Figure 4
OR of prematurity. The pooled estimate of prematurity for patients taking HCQ compared to placebo was determined.Pediatric Rheumatology 2009, 7:9 http://www.ped-rheum.com/content/7/1/9
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women taking the drug during pregnancy [35-37]. Two of
these studies performed comprehensive ophthalmologic
examinations of infants whose mothers took HCQ during
pregnancy and found no evidence of ocular toxicity
[29,31]. All of these studies have documented the safety of
HCQ in infants whose mothers took the medication dur-
ing pregnancy. The total number of infants examined in
these 3 studies is 96.
Another benefit of HCQ during pregnancy is its effect on
reducing disease activity. Of note Clowse et al. [27] and
Levy et al. [31] made observations of lupus outcomes in a
cohort of women with SLE and reported the impact of
HCQ treatment cessation on SLE activity during preg-
nancy. Clowse et al. [27] found that women who stopped
taking HCQ had increased lupus activity and increased
lupus flares during pregnancy. High activity lupus was
defined as a physician's estimate of activity (PEA) greater
than 2 occurred in twice as many pregnancies in which
HCQ treatment was stopped as in those in which HCQ
was continued. The rate of flare was also higher among
women who stopped the medication compared with
those who either continued taking it or who never took it.
These flares occurred throughout pregnancy. More
women who discontinued HCQ treatment had SLEDAI
scores greater than 4 during pregnancy and this remained
elevated when adjusted for year of delivery, anti-phos-
pholipid antibody syndrome (APS), age, ethnicity, and
prior history of lupus nephritis.
The types of lupus activity that were best controlled by
HCQ were arthritis and constitutional symptoms. HCQ
did not prevent the more severe complications of pro-
teinuria or thrombocytopenia. Furthermore, the authors
also evaluated the use of Prednisone and fewer women
who continued HCQ required high-dose corticosteroids,
defined as either a daily dose of Prednisone of at least 20
mg or pulse steroids. Similar to the observation of Clowse
et al. [27], Levy et al. [31] noted that after delivery Sys-
temic Lupus Erythematosus Disease Activity Index
(SLEDAI) scores of the placebo group were not signifi-
cantly different from pre-treatment scores while in the
HCQ group a statistically significant improvement in the
score was found; in the HCQ group there were no flares,
and there was a statistically significant improvement in
the SLEDAI score at delivery when compared to the pla-
cebo group.
Conclusion
In conclusion, based on the findings of this meta-analysis,
HCQ is not associated with any increased risk of congen-
ital defect, spontaneous abortion, fetal death, pre-matu-
rity or decreased numbers of live births in pregnant
patients with auto-immune diseases. Our data demon-
strate that HCQ is safe for use during pregnancy.
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